Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
- Author
- BISSLER, John J1 ; CHRISTOPHER KINGSWOOD, J2 ; WHITTEMORE, Vicky H11 ; CHEN, David12 ; SAHMOUD, Tarek12 ; SHAH, Gaurav12 ; LINCY, Jeremie13 ; LEBWOHL, David12 ; BUDDE, Klemens9 ; RADZIKOWSKA, Elżbteta3 ; ZONNENBERG, Bernard A4 ; FROST, Michael5 ; BELOUSOVA, Elena6 ; SAUTER, Matthias7 ; NONOMURA, Norio8 ; BRAKEMEIER, Susanne9 ; DE VRIES, Petrus J10
[1] Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
[2] Royal Sussex County Hospital, Brighton, United Kingdom
[3] National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
[4] Universitair Medisch Centrum, Utrecht, Netherlands
[5] Minnesota Epilepsy Group, St Paul, MN, United States
[6] Moscow Research Institute of Pediatrics & Pediatric Surgery, Moscow, Russian Federation
[7] Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
[8] Osaka University Hospital, Osaka, Japan
[9] Charite Universitätsmedizin, Berlin, Germany
[10] Division of Child & Adolescent Psychiatry, University of Cape Town, South Africa
[11] National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States
[12] Novartis Pharmaceuticals Corporation, Florham Park, NJ, United States
[13] Novartis Pharmaceuticals Corporation, Basel, Switzerland - Source
Lancet (British edition). 2013, Vol 381, Num 9869, pp 817-824, 8 p ; ref : 30 ref
- CODEN
- LANCAO
- ISSN
- 0140-6736
- Scientific domain
- General medicine general surgery
- Publisher
- Elsevier, Kidlington
- Publication country
- United Kingdom
- Document type
- Article
- Language
- Russian
- Keyword (fr)
- Angiomyolipome Antibactérien Association Complexe Complexité Essai clinique Etude double insu Etude multicentrique Evérolimus Immunodépresseur Médecine Phacomatose de Bourneville Sporadique Essai randomisé contrôlé Inhibiteur mTOR Lymphangiomyomatose Inhibiteur synthèse protéique Lactone Macrolide Maladie héréditaire Pathologie du système nerveux Tumeur
- Keyword (en)
- Angiomyolipoma Antibacterial agent Association Complexes Complexity Clinical trial Double blind study Multicenter study Everolimus Immunosuppressive agent Medicine Bourneville syndrome Sporadic Randomized controlled trial Lymphangiomyomatosis Protein synthesis inhibitor Lactone Macrolide Genetic disease Nervous system diseases Tumor
- Keyword (es)
- Angiomiolipoma Antibacteriano Asociación Complejo Complejidad Ensayo clínico Estudio doble ciego Estudio multicéntrico Everolimus Inmunodepresor Medicina Facomatosis Bourneville Esporádico Ensayo aleatorio controlado Inhibidor síntesis proteica Lactona Macrólido Enfermedad hereditaria Sistema nervioso patología Tumor
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02S Antibiotics. Antiinfectious agents. Antiparasitic agents / 002B02S02 Antibacterial agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17E Tumors of the nervous system. Phacomatoses
- Discipline
- Generalities in medical sciences Neurology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27042633
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0140-6736(12)61767-X 
https://dx.doi.org/10.1016/S0140-6736(12)61767-X
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)61767-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:186:\"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"381\";s:8:\"\u0000*\u0000issue\";s:4:\"9869\";s:8:\"\u0000*\u0000spage\";s:3:\"817\";s:8:\"\u0000*\u0000epage\";s:3:\"824\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"BISSLER\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:24:\"CHRISTOPHER KINGSWOOD, J\";i:1;s:19:\"WHITTEMORE, Vicky H\";i:2;s:11:\"CHEN, David\";i:3;s:14:\"SAHMOUD, Tarek\";i:4;s:12:\"SHAH, Gaurav\";i:5;s:14:\"LINCY, Jeremie\";i:6;s:14:\"LEBWOHL, David\";i:7;s:14:\"BUDDE, Klemens\";i:8;s:22:\"RADZIKOWSKA, El\u017cbteta\";i:9;s:21:\"ZONNENBERG, Bernard A\";i:10;s:14:\"FROST, Michael\";i:11;s:16:\"BELOUSOVA, Elena\";i:12;s:16:\"SAUTER, Matthias\";i:13;s:15:\"NONOMURA, Norio\";i:14;s:19:\"BRAKEMEIER, Susanne\";i:15;s:18:\"DE VRIES, Petrus J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:186:\"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)61767-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:186:\"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"381\";s:8:\"\u0000*\u0000issue\";s:4:\"9869\";s:8:\"\u0000*\u0000spage\";s:3:\"817\";s:8:\"\u0000*\u0000epage\";s:3:\"824\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"BISSLER\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:24:\"CHRISTOPHER KINGSWOOD, J\";i:1;s:19:\"WHITTEMORE, Vicky H\";i:2;s:11:\"CHEN, David\";i:3;s:14:\"SAHMOUD, Tarek\";i:4;s:12:\"SHAH, Gaurav\";i:5;s:14:\"LINCY, Jeremie\";i:6;s:14:\"LEBWOHL, David\";i:7;s:14:\"BUDDE, Klemens\";i:8;s:22:\"RADZIKOWSKA, El\u017cbteta\";i:9;s:21:\"ZONNENBERG, Bernard A\";i:10;s:14:\"FROST, Michael\";i:11;s:16:\"BELOUSOVA, Elena\";i:12;s:16:\"SAUTER, Matthias\";i:13;s:15:\"NONOMURA, Norio\";i:14;s:19:\"BRAKEMEIER, Susanne\";i:15;s:18:\"DE VRIES, Petrus J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:186:\"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)61767-X\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)61767-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:186:\"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"381\";s:8:\"\u0000*\u0000issue\";s:4:\"9869\";s:8:\"\u0000*\u0000spage\";s:3:\"817\";s:8:\"\u0000*\u0000epage\";s:3:\"824\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"BISSLER\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:24:\"CHRISTOPHER KINGSWOOD, J\";i:1;s:19:\"WHITTEMORE, Vicky H\";i:2;s:11:\"CHEN, David\";i:3;s:14:\"SAHMOUD, Tarek\";i:4;s:12:\"SHAH, Gaurav\";i:5;s:14:\"LINCY, Jeremie\";i:6;s:14:\"LEBWOHL, David\";i:7;s:14:\"BUDDE, Klemens\";i:8;s:22:\"RADZIKOWSKA, El\u017cbteta\";i:9;s:21:\"ZONNENBERG, Bernard A\";i:10;s:14:\"FROST, Michael\";i:11;s:16:\"BELOUSOVA, Elena\";i:12;s:16:\"SAUTER, Matthias\";i:13;s:15:\"NONOMURA, Norio\";i:14;s:19:\"BRAKEMEIER, Susanne\";i:15;s:18:\"DE VRIES, Petrus J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:186:\"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)61767-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:186:\"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"381\";s:8:\"\u0000*\u0000issue\";s:4:\"9869\";s:8:\"\u0000*\u0000spage\";s:3:\"817\";s:8:\"\u0000*\u0000epage\";s:3:\"824\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"BISSLER\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:24:\"CHRISTOPHER KINGSWOOD, J\";i:1;s:19:\"WHITTEMORE, Vicky H\";i:2;s:11:\"CHEN, David\";i:3;s:14:\"SAHMOUD, Tarek\";i:4;s:12:\"SHAH, Gaurav\";i:5;s:14:\"LINCY, Jeremie\";i:6;s:14:\"LEBWOHL, David\";i:7;s:14:\"BUDDE, Klemens\";i:8;s:22:\"RADZIKOWSKA, El\u017cbteta\";i:9;s:21:\"ZONNENBERG, Bernard A\";i:10;s:14:\"FROST, Michael\";i:11;s:16:\"BELOUSOVA, Elena\";i:12;s:16:\"SAUTER, Matthias\";i:13;s:15:\"NONOMURA, Norio\";i:14;s:19:\"BRAKEMEIER, Susanne\";i:15;s:18:\"DE VRIES, Petrus J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:186:\"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)61767-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:186:\"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"381\";s:8:\"\u0000*\u0000issue\";s:4:\"9869\";s:8:\"\u0000*\u0000spage\";s:3:\"817\";s:8:\"\u0000*\u0000epage\";s:3:\"824\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"BISSLER\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:24:\"CHRISTOPHER KINGSWOOD, J\";i:1;s:19:\"WHITTEMORE, Vicky H\";i:2;s:11:\"CHEN, David\";i:3;s:14:\"SAHMOUD, Tarek\";i:4;s:12:\"SHAH, Gaurav\";i:5;s:14:\"LINCY, Jeremie\";i:6;s:14:\"LEBWOHL, David\";i:7;s:14:\"BUDDE, Klemens\";i:8;s:22:\"RADZIKOWSKA, El\u017cbteta\";i:9;s:21:\"ZONNENBERG, Bernard A\";i:10;s:14:\"FROST, Michael\";i:11;s:16:\"BELOUSOVA, Elena\";i:12;s:16:\"SAUTER, Matthias\";i:13;s:15:\"NONOMURA, Norio\";i:14;s:19:\"BRAKEMEIER, Susanne\";i:15;s:18:\"DE VRIES, Petrus J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:186:\"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
